Mayo Clinic and nference today launched a startup, Qrativ, focused on drug development driven by artificial intelligence. The company, backed by a $8.3 million Series A round, plans to combine nference’s AI platform and Mayo Clinic’s clinical data.
Qrativ hopes to use AI to discover potential new therapeutic indications for drugs earlier in development, in an effort to identify new treatments for rare conditions.
Get the full story at our sister site, Drug Delivery Business News.
The post Mayo Clinic, nference launch startup to leverage AI for drug development appeared first on MassDevice.